Show simple item record

dc.contributor.authorSteward, William P
dc.contributor.authorScarffe, J Howard
dc.contributor.authorDexter, T Michael
dc.contributor.authorTesta, Nydia G
dc.date.accessioned2010-08-18T15:11:49Z
dc.date.available2010-08-18T15:11:49Z
dc.date.issued1990
dc.identifier.citationClinical application of hematopoietic growth factors. 1990, 49:359-78 Immunol. Ser.en
dc.identifier.issn0092-6019
dc.identifier.pmid2090257
dc.identifier.urihttp://hdl.handle.net/10541/109857
dc.description.abstractAlthough many questions remain about the clinical use of hemopoietic growth factors, it is remarkable how much information has been gained in such a short time. There is enormous interest in these agents among physicians from a variety of specialties--all providing new ideas for potential studies. As the supplies increase, many new trials can be opened. It is important to design these studies with due regard to the results of in vitro and in vivo preclinical experiments--preferably after discussion with experimental hematologists--or vital information will be missed. There can have been few more exciting developments in clinical medicine in the recent past than the availability of the hemopoietic growth factors and, hopefully, it will not be long before the preliminary trials are completed and these agents are accepted for routine use to the benefit of a large number of patients.
dc.language.isoenen
dc.subjectAnticancerous Agentsen
dc.subjectCanceren
dc.subjectHaematopoiesisen
dc.subjectHaematopoietic Cell Growth Factorsen
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents
dc.subject.meshHematopoiesis
dc.subject.meshHematopoietic Cell Growth Factors
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.titleClinical application of hematopoietic growth factors.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, England.en
dc.identifier.journalImmunology Seriesen
html.description.abstractAlthough many questions remain about the clinical use of hemopoietic growth factors, it is remarkable how much information has been gained in such a short time. There is enormous interest in these agents among physicians from a variety of specialties--all providing new ideas for potential studies. As the supplies increase, many new trials can be opened. It is important to design these studies with due regard to the results of in vitro and in vivo preclinical experiments--preferably after discussion with experimental hematologists--or vital information will be missed. There can have been few more exciting developments in clinical medicine in the recent past than the availability of the hemopoietic growth factors and, hopefully, it will not be long before the preliminary trials are completed and these agents are accepted for routine use to the benefit of a large number of patients.


This item appears in the following Collection(s)

Show simple item record